353 related articles for article (PubMed ID: 28801400)
1. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
[TBL] [Abstract][Full Text] [Related]
2. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.
Dalla Bella E; Bersano E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Filosto M; Giannini F; Spataro R; Lunetta C; Mandrioli J; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Tugnoli V; Verriello L; Volanti P; Furlan R; Nolan JM; Abgueguen E; Tramacere I; Lauria G
Brain; 2021 Oct; 144(9):2635-2647. PubMed ID: 33905493
[TBL] [Abstract][Full Text] [Related]
3. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
4. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
[TBL] [Abstract][Full Text] [Related]
5. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.
Vieira FG; Ping Q; Moreno AJ; Kidd JD; Thompson K; Jiang B; Lincecum JM; Wang MZ; De Zutter GS; Tassinari VR; Levine B; Hatzipetros T; Gill A; Perrin S
PLoS One; 2015; 10(8):e0135570. PubMed ID: 26288094
[TBL] [Abstract][Full Text] [Related]
6. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis.
Wang L; Popko B; Tixier E; Roos RP
Neurobiol Dis; 2014 Nov; 71():317-24. PubMed ID: 25134731
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
[TBL] [Abstract][Full Text] [Related]
8. Study protocol of RESCUE-ALS: A Phase 2,
Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
[TBL] [Abstract][Full Text] [Related]
9. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
10. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
[TBL] [Abstract][Full Text] [Related]
12. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
[TBL] [Abstract][Full Text] [Related]
13. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
[TBL] [Abstract][Full Text] [Related]
14. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M;
Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K;
Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398
[TBL] [Abstract][Full Text] [Related]
17. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
[TBL] [Abstract][Full Text] [Related]
18. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
19. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit.
Das I; Krzyzosiak A; Schneider K; Wrabetz L; D'Antonio M; Barry N; Sigurdardottir A; Bertolotti A
Science; 2015 Apr; 348(6231):239-42. PubMed ID: 25859045
[TBL] [Abstract][Full Text] [Related]
20. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
; Morrison KE; Dhariwal S; Hornabrook R; Savage L; Burn DJ; Khoo TK; Kelly J; Murphy CL; Al-Chalabi A; Dougherty A; Leigh PN; Wijesekera L; Thornhill M; Ellis CM; O'Hanlon K; Panicker J; Pate L; Ray P; Wyatt L; Young CA; Copeland L; Ealing J; Hamdalla H; Leroi I; Murphy C; O'Keeffe F; Oughton E; Partington L; Paterson P; Rog D; Sathish A; Sexton D; Smith J; Vanek H; Dodds S; Williams TL; Steen IN; Clarke J; Eziefula C; Howard R; Orrell R; Sidle K; Sylvester R; Barrett W; Merritt C; Talbot K; Turner MR; Whatley C; Williams C; Williams J; Cosby C; Hanemann CO; Iman I; Philips C; Timings L; Crawford SE; Hewamadduma C; Hibberd R; Hollinger H; McDermott C; Mils G; Rafiq M; Shaw PJ; Taylor A; Waines E; Walsh T; Addison-Jones R; Birt J; Hare M; Majid T
Lancet Neurol; 2013 Apr; 12(4):339-45. PubMed ID: 23453347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
